|
|
| |
|
WEDNESDAY, MAY 26, 2004 |
|
PRE-MEETING SPONSORED SYMPOSIA
|
08:30-10:00 |
LIVE VIRAL VACCINES:
FROM EARLY DEVELOPMENT TO IMPLEMENTATION
(Sponsored by Aventis Pasteur MSD) |
 |
Chair: T. VESIKARI, TAMPERE, FINLAND
Co-chair: L. HESSEL, LYON, FRANCE |
| 8:30 |
Introduction
L. HESSEL, LYON, FRANCE
|
|
| 8:35 |
Early development of viral vaccines
A. SHAW, WEST POINT, USA
|
|
| 8:55 |
Safety issues with viral vaccines: the rotavirus
vaccine experience
L. GOTHEFORS, UMEA, SWEDEN
|
|
| 9:15 |
Assessing the impact of viral vaccines:
the Varicella vaccine experience
I. BARBERI, MESSINA, ITALY
|
|
| 9:35 |
Implementing vaccination programmes with
viral vaccines: the MMR vaccine experience
A. FINN, BRISTOL, UK
|
|
| 9:55 |
Conclusion
T. VESIKARI, TAMPERE, FINLAND
|
|
|
| |
|
|
|
| |
Chair: R. DAGAN, ISRAEL
Co-chair: H. BOGAERTS, BELGIUM
|
|
| 10:30 |
MMR VACCINATION: Rationale for an accelerated 2-dose
schedule
J. SCHMITT, GERMANY
|
|
| 11:00 |
ROTAVIRUS VACCINE: Worldwide Health Impact
T. VESIKARI, FINLAND
|
|
| 11:30 |
ROUTINE HEPATITIS A VACCINATION: successful implementation
R. DAGAN, ISRAEL
|
|
| 12:00 |
NEXT WAVES IN ADOLESCENT VACCINES: Preparing for HPV
Vaccines
X. BOSCH, SPAIN
|
|
|
| |
|
| 13:00-14:30 |
MENINGOCOCCAL VACCINES - EXPERIENCES AND FUTURE
(sponsored by Chiron Vaccines)
|
 |
| Chair: |
RICHARD MOXON, OXFORD,
UK
ANDREW J. POLLARD, OXFORD, UK |
|
| |
Meningitis and Meningococcal Disease: Views from the
Front Line
D. HOLT, MENINGITIS TRUST UK |
|
| |
Epidemiology of meningococcal disease and
implications for the protection afforded by meningococcal
conjugate vaccines
A.J. POLLARD, OXFORD UNIVERSITY VACCINES GROUP,
UK |
|
| |
Induction of immunological memory and comparison
of the safety, reactogenicity and immunogenicity of a
meningococcal C conjugate vaccine (MCC) when administered
concomitantly with DTaP-IPV-HBV/Hib vaccine to infants
in a 2 or in a 3 dose schedule
J. SCHMITT, STIKO, GERMANY |
|
| |
Future of Meningococcal vaccines - challenges
and achievements
R. MOXON, OXFORD UNIVERSITY VACCINES GROUP, UK |
|
| |
Control of New Zealand´s Fourteen
Year Meningococcal Epidemic
D. LENNON, UNIVERSITY OF AUCKLAND, NEW ZEALAND |
|
|
| |
|
| 15:00-16:30 |
INNOVATIVE VACCINES: NEW OPPORTUNITIES
TO ADVANCE PAEDIATRIC HEALTH
(sponsored by
Wyeth) |
 |
| Chair: |
TERHO HEIKKINEN, TURKU,FINLAND |
|
| |
Seven Valent Pneumococcal Conjugate Vaccine and Pneumonia
Vaccine Effectiveness: An Update from the Prelicensure
Trial
STEVE BLACK, USA |
|
| |
Impact of the Introduction of Pneumococcal
Conjugate Vaccine on the Epidemiology of Invasive Disease
in Children and Adults within Northern California Kaiser
Permanente (NCKP)
HENRY SHINEFIELD, USA |
|
| |
Preventing Invasive Pneumococcal Disease
in Italy: The Potential of the 7-Valent Pneumococcal Conjugate
Vaccine
NICOLA PRINCIPI, ITALY |
|
| |
The Control of Influenza in Children
TERHO HEIKKINEN, FINLAND |
|
| |
There will be an audience response system
provided during the symposium. |
|
|
| |
|
| 17:00-18:30 |
Symposium:
DO WE NEED BETTER VACCINES?
(sponsored by Baxter Vaccine AG)
|
| |
| Chair: |
STANLEY A. PLOTKIN, USA |
| |
The Evolution of Vaccination in the Past and in the
Future
STANLEY A. PLOTKIN, DOYLESTOWN PA, USA |
| |
Experiences with Meningococcal Vaccines
JULIO A. VAZQUEZ, INSTITUTO DE SALUD CARLOS III,
SPAIN |
| |
State of the Art Vaccines Against Bacterial and Viral
Diseases
HARTMUT J. EHRLICH, BAXTER VACCINES, AUSTRIA |
| |
Baxter Vaccines: Technology Platforms for the Future
NOEL BARRETT, BAXTER VACCINES, AUSTRIA
|
|
| |
|
| 17:00-18:30 |
 OPTIMIZING
TREATMENT FOR PEDIATRIC URTIs
(sponsored by Pfizer
Inc)
| Chair: |
OLLI RUUSKANEN, FINLAND
URS B SCHAAD, SWITZERLAND |
|
| |
| 17:00 |
Welcome and Opening Remarks
OLLI RUUSKANEN, FINLAND |
|
| 17:05 |
Compliance of pediatric patients with prescribed
antibiotics: The Potential Impact on Bacterial Resistance
URS B SCHAAD, SWITZERLAND |
|
| 17:25 |
Can RTIs in Children be Treated by a Single
Dose of an Antibiotic?
JEFF BLUMER, USA |
|
| 17:50 |
Single-Dose Azithromycin versus High-Dose
Amoxicillin in the Treatment of AOM
ADRIANO ARGUEDAS, COSTA RICA |
|
| 18:10 |
Panel Discussion |
|
| 18:25 |
Concluding Remarks
URS B SCHAAD, SWITZERLAND |
|
|
|
|
|
